Retrophin competitorsClear all

Retrophin's top competitors include Albumedix, Ventria Bioscience, Acticor Biotech and Omeros.
Retrophin
Retrophin
Retrophin is a biopharmaceutical company which focuses on the development, acquisition, and commercialization of therapies for the treatment of serious or rare diseases.
Albumedix
Albumedix
Albumedix develops bio-therapeutics formulations for advanced drug and vaccine formulation intended to improve therapies for people with serious diseases.
Ventria Bioscience
Ventria Bioscience
Ventria Bioscience develops life-saving medicines targeting inflammatory, infectious and gastrointestinal diseases.
Acticor Biotech
Acticor Biotech
Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.
Omeros
Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.
Founding Date
Founding Date
2011
Founding Date
2016
Founding Date
1993
Founding Date
2013
Founding Date
1994
Type
Type
Public
Type
Private
Type
Private
Type
Private
Type
Public
Tags
Locations
Locations
San Diego, US HQ
Dublin, IE
Cambridge, US
Locations
Nottinghamshire, GB HQ
Locations
Junction City, US HQ
Aurora, US
Locations
Paris, FR HQ
Paris, FR
Locations
Seattle, US HQ
Employees
Employees
2213% increase
Employees
675% increase
Employees
313% decrease
Employees
18
Employees
2589% increase
Valuation ($)
Valuation ($)
900 m
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
N/A
Valuation ($)
628.9 m
Twitter followers
Twitter followers
14
Twitter followers
134
Twitter followers
N/A
Twitter followers
322
Twitter followers
239
Alexa Website Rank
Alexa Website Rank
302733
Alexa Website Rank
412348
Alexa Website Rank
N/A
Alexa Website Rank
257693
Alexa Website Rank
337813
Employee Rating
Employee Rating
4.2
Employee Rating
N/A
Employee Rating
1.4
Employee Rating
N/A
Employee Rating
3.3

Financial

Revenue (est.)
Revenue (est.)
$175.3m (FY, 2019)
Revenue (est.)
£26.1m (FY, 2018)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$111.8m (FY, 2019)
Cost of goods
Cost of goods
$5.2m (FY, 2019)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$865k (FY, 2019)
Gross profit
Gross profit
$170.1m (FY, 2019)
Gross profit
N/A
Gross profit
N/A
Gross profit
N/A
Gross profit
$110.9m (FY, 2019)
Net income
Net income
($146.4m) (FY, 2019)
Net income
£5m (FY, 2018)
Net income
N/A
Net income
N/A
Net income
($84.5m) (FY, 2019)

Funding

Total funding raised
Total funding raised
$ 116m
Total funding raised
N/A
Total funding raised
$ 7.7m
Total funding raised
$ 33.3m
Total funding raised
$ 354.8m
For sources of this data, please see the company profile

View company profiles

Albumedix
HQ
Nottinghamshire, GB
Employees
67↑ 5% increase

Albumedix develops bio-therapeutics formulations for advanced drug and vaccine formulation intended to improve therapies for people with serious diseases.

View company
Ventria Bioscience
HQ
Junction City, US
Employees
31↓ 3% decrease

Ventria Bioscience develops life-saving medicines targeting inflammatory, infectious and gastrointestinal diseases.

View company
Acticor Biotech
HQ
Paris, FR
Employees
18

Acticor Biotech is a biopharmaceutical company developing an antithrombotic agent for the treatment of the acute phase of ischemic stroke.

View company
Omeros
HQ
Seattle, US
Employees
258↑ 9% increase

Omeros Corporation is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.

View company